Completed PHASE2 NCT00001212

Drug Therapy in Lupus Nephropathy

Immunosuppressive Drug Therapy in Membranous Lupus Nephropathy

Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Conditions Nephrotic Syndrome Systemic Lupus Erythematosus

Interventions cyclophosphamide cyclosporin A prednisone

Updated 5 times since 2017 Last updated: Apr 8, 2008 Started: Nov 30, 1986 Completion: Sep 30, 2004

This PHASE2 trial investigates Nephrotic Syndrome and Systemic Lupus Erythematosus and is currently completed. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) leads this study, which shows 5 recorded versions since 1986 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Nov 1986

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Data source: National Institutes of Health Clinical Center (CC)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bethesda, United States